On 13 September 2024, Pharmac, the New Zealand Pharmaceutical Management Agency, announced a proposal to fund four new cancer and respiratory treatments through a provisional partnership with AstraZeneca, commencing 1 January 2025. The proposal includes the following AstraZeneca treatments involving biologics:
- Enhertu® (trastuzumab deruxtecan) for the treatment of HER2 positive metastatic breast cancer; and
- Synagis® (palivizumab) for prevention of severe illness caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV.
Pharmac is seeking feedback on the proposal by email before 4pm, Monday 7 October 2024.